Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oritavancin Dosing in cSSSI (SIMPLIFI)
NCT00514527Phase 2Completed
- Sponsor
- Targanta Therapeutics Corporation
- Start
- Aug 2007
- Primary completion
- Apr 2008
- Modality
- Peptides, Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of oritavancin in Skin and Skin Structure Infection (SSSI) (3 arms), sponsored by Targanta Therapeutics Corporation. Primary endpoints: Clinical success at follow-up at 6 months and Clinical response at Test of Cure. Started Aug 2007; status: completed.
02
Drugs
oritavancin
03
Conditions
Skin and Skin Structure Infection (SSSI)
Beyond the preview
Go deeper on NCT00514527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00514527.